DYRK1A and progressive supranuclear palsy: We also compared levels of plasma DYRK1A from patients with various tauopathies in the SHATAU7-IMATAU cohort: frontotemporal lobar degeneration, hippocampal sclerosis, and progressive supranuclear palsy and corticobasal degeneration.